European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumococcal infections - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. see sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.the use of vaxneuvance should be in accordance with official recommendations.

Israel - English - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:- active immunisation of adults, including pregnant women, and children from 6 months of age and older- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women.the use of vaxigrip tetra should be based on official recommendations.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - fluarix tetra is indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - powder and solution for solution for injection - meningococcal vaccines group y 5 mcg / 0.5 ml; meningococcal vaccines group w 5 mcg / 0.5 ml; meningococcal vaccines group c 5 mcg / 0.5 ml; meningococcal vaccines group a 10 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.

United States - English - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (mdck cell derived, propiolactone inactivated) (unii: qwjhw3wexs) (influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:55qh9pjkdv), influenza a virus a/north carolina/04/2016 (h3n2) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) (unii: 0b3am58j28) (influenza a virus a/north carolina/04/2016 (h3n2) hemagglutinin antigen (mdck cell derived, pr - flucelvax quadrivalent is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes a and type b contained in the vaccine. flucelvax quadrivalent is approved for use in persons 4 years of age and older. for children and adolescents 4 through 17 years of age, approval is based on the immune response elicited by flucelvax quadrivalent. data demonstrating a decrease in influenza disease after vaccination of this age group with flucelvax quadrivalent are not available. [see clinical studies (14)] do not administer flucelvax quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine [see description (11) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to flucelvax quadrivalent during pregnancy. women who are vaccinated with flucelvax quadrivalent during pregnancy are encouraged to enroll in the registry by calling

Canada - English - Health Canada

merck canada inc - recombinant human papillomavirus type 6 l1 protein; recombinant human papillomavirus type 11 l1 protein; recombinant human papillomavirus type 16 l1 protein; recombinant human papillomavirus type 18 l1 protein - suspension - 20mcg; 40mcg; 40mcg; 20mcg - recombinant human papillomavirus type 6 l1 protein 20mcg; recombinant human papillomavirus type 11 l1 protein 40mcg; recombinant human papillomavirus type 16 l1 protein 40mcg; recombinant human papillomavirus type 18 l1 protein 20mcg - vaccines

Canada - English - Health Canada

merck canada inc - recombinant human papillomavirus type 6 l1 protein; recombinant human papillomavirus type 11 l1 protein; recombinant human papillomavirus type 16 l1 protein; recombinant human papillomavirus type 18 l1 protein; recombinant human papillomavirus type 31 l1 protein; recombinant human papillomavirus type 33 l1 protein; recombinant human papillomavirus type 45 l1 protein; recombinant human papillomavirus type 52 l1 protein; recombinant human papillomavirus type 58 l1 protein - suspension - 30mcg; 40mcg; 60mcg; 40mcg; 20mcg; 20mcg; 20mcg; 20mcg; 20mcg - recombinant human papillomavirus type 6 l1 protein 30mcg; recombinant human papillomavirus type 11 l1 protein 40mcg; recombinant human papillomavirus type 16 l1 protein 60mcg; recombinant human papillomavirus type 18 l1 protein 40mcg; recombinant human papillomavirus type 31 l1 protein 20mcg; recombinant human papillomavirus type 33 l1 protein 20mcg; recombinant human papillomavirus type 45 l1 protein 20mcg; recombinant human papillomavirus type 52 l1 protein 20mcg; recombinant human papillomavirus type 58 l1 protein 20mcg - vaccines

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - human papillomavirus type 11 l1; human papillomavirus type 16 l1; human papillomavirus type 18 l1; human papillomavirus type 6 l1; human papillomavirus type 31 l1; human papillomavirus type 33 l1; human papillomavirus type 45 l1; human papillomavirus type 52 l1; human papillomavirus type 58 l1 -

Canada - English - Health Canada

sanofi pasteur limited - haemagglutinin-strain a (h1n1); haemagglutinin-strain a (h3n2); haemagglutinin-strain b (victoria); haemagglutinin-strain b (yamagata) - suspension - 60mcg; 60mcg; 60mcg; 60mcg - haemagglutinin-strain a (h1n1) 60mcg; haemagglutinin-strain a (h3n2) 60mcg; haemagglutinin-strain b (victoria) 60mcg; haemagglutinin-strain b (yamagata) 60mcg - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pneumococcal purified capsular polysaccharides, quantity: 2.2 microgram; pneumococcal purified capsular polysaccharides, quantity: 4.4 microgram - injection, suspension - excipient ingredients: aluminium phosphate; succinic acid; sodium chloride; water for injections; polysorbate 80; diphtheria crm197 protein - active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 8, 9v, 10a, 11a, 12f, 14, 15b, 18c, 19a, 19f, 22f, 23f, and 33f in individuals from 6 weeks of age and older.,prevenar 20 may not prevent disease caused by s. pneumoniae serotypes that are not contained in the vaccine.,prevenar 20 should be used in accordance with official recommendations.